19 Nov 2026, 09:40
ReinstatementMS
Announcement history available from 1 August 2025
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 19 Nov 2026, 09:40 | Reinstatement to Quotation | Reinstatement | MS | 09002 | |
| 19 Nov 2026, 08:32 | ACW XanaMIA Alzheimers trial results | Company Update | MS | 03026, 11001, 14014 | |
| 17 Nov 2026, 10:33 | Suspension from Quotation | Trading Halt / Suspension | MS | 09001 | |
| 13 Nov 2026, 09:25 | Request for Trading Halt | Other | — | 09016 | |
| 13 Nov 2026, 09:22 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 12 Nov 2026, 16:29 | Notification of cessation of securities - ACW | Securities Administration | — | 06027 | |
| 12 Nov 2026, 16:28 | Update - Notification of buy-back - ACW | Buybacks & Capital Management | — | 06022 | |
| 9 Nov 2026, 16:31 | Response to ASX Price Query | ASX Query | MS | 17003 | |
| 28 Oct 2026, 10:57 | Letter to Shareholders, Notice of AGM & Proxy Form | Meetings & Governance | — | 08001, 08004, 16002 | |
| 26 Oct 2026, 14:16 | Actinogen receives $10.8m R&D tax incentive rebate from ATO | Capital Raising | MS | 03014, 03022 | |
| 21 Oct 2026, 08:55 | ACW pivotal Alzheimers trial database lock - results mid-Nov | Company Update | MS | 11001 | |
| 19 Oct 2026, 09:57 | ACW September 2026 quarterly activity report & Appendix 4C | Quarterly Reports | MS | 14014, 19001, 19006 | |
| 12 Oct 2026, 12:41 | Notification of buy-back - ACW | Other | — | 06023 | |
| 9 Oct 2026, 09:10 | AGM date and closing date for director nominations | Meetings & Governance | — | 08006 | |
| 30 Sept 2026, 13:04 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 23 Sept 2026, 12:35 | Options underwriting cleansing notice | Securities Administration | — | 06018 | |
| 23 Sept 2026, 12:35 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 23 Sept 2026, 12:34 | Underwriting of unlisted options completed | Securities Administration | MS | 06009 | |
| 23 Sept 2026, 08:47 | ACW Alzheimers pivotal trial completes last patient visit | Company Update | MS | 11001 | |
| 16 Sept 2026, 12:43 | Notification of cessation of securities - ACW | Securities Administration | — | 06027 | |
| 15 Sept 2026, 14:34 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 11 Sept 2026, 15:54 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 9 Sept 2026, 12:54 | Appendix 3Y-Dr Geoffrey Brooke | Director Interests | — | 02009 | |
| 9 Sept 2026, 12:40 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 9 Sept 2026, 10:11 | ACW CMO international Xanamem presentation | Presentations | — | 03026 | |
| 8 Sept 2026, 14:52 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 7 Sept 2026, 16:39 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 4 Sept 2026, 15:55 | Response to ASX Price Query | ASX Query | MS | 17003 | |
| 3 Sept 2026, 15:04 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 1 Sept 2026, 10:14 | Proposed issue of securities - ACW | Securities Administration | — | 06013 | |
| 1 Sept 2026, 10:12 | ACW unlisted options fully underwritten | Company Update | MS | 06009, 11001 | |
| 28 Aug 2026, 15:58 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 28 Aug 2026, 14:46 | Appendix 3Y-Dr George Morstyn | Director Interests | — | 02009 | |
| 28 Aug 2026, 14:43 | Appendix 3Y-Dr Geoffrey Brooke | Director Interests | — | 02009 | |
| 28 Aug 2026, 14:36 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 27 Aug 2026, 16:42 | Appendix 4G | Company Administration | — | 03025 | |
| 27 Aug 2026, 16:41 | Corporate Governance Statement | Company Administration | — | 03024 | |
| 27 Aug 2026, 16:27 | ACW FY2026 results and outlook | Financial Results | MS | 03003 | |
| 27 Aug 2026, 16:26 | ACW Appendix 4E and 2026 annual report | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 20 Aug 2026, 14:46 | Appendix 3Y - Dr George Morstyn | Director Interests | — | 02009 | |
| 20 Aug 2026, 14:40 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 17 Aug 2026, 14:26 | Appendix 3Y-Malcolm McComas | Director Interests | — | 02009 | |
| 17 Aug 2026, 14:14 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 12 Aug 2026, 09:14 | ACW webinar today, The future of Alzheimers treatment | Presentations | — | 03026, 14014 | |
| 10 Aug 2026, 16:38 | Updated Securities Trading Policy | Company Administration | — | 14013 | |
| 10 Aug 2026, 11:33 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 10 Aug 2026, 09:12 | Notification of cessation of securities - ACW | Securities Administration | — | 06027 | |
| 6 Aug 2026, 08:27 | ACW Bioshares presentation, strong cortisol rationale | Presentations | — | 03026 | |
| 5 Aug 2026, 12:43 | Application for quotation of securities - ACW | Securities Administration | — | 06020 | |
| 5 Aug 2026, 12:08 | ACW webinar on the future of Alzheimers treatment | Presentations | — | 14014 |